Table 1 Description of the abatacept clinical trials included in the current analysis
Study name | Study design/study title/DB enrollment period | Duration of double-blind period (months) | abatacept | PBO | Open-label extension |
|---|---|---|---|---|---|
IM101101 [6] Phase IIB | Randomized, placebo-controlled, double-blind/2001 to 2002 | 12 | 85 | 36 | 80 |
Randomized, dose-ranging, placebo-controlled, double-blind/2001 to 2002 | 12 | 220 | 119 | 219 | |
ATTAIN [9] IM101029 Phase III | Randomized, placebo-controlled, double-blind/Abatacept Trial in Treatment of Anti-TNF INadequate responders/2002 to 2003 | 6 | 258 | 133 | 317 |
AIM [10] IM101102 Phase III | Randomized, placebo controlled, double-blind/Abatacept in Inadequate responders to MTX/2002 to 2003 | 12 | 433 | 219 | 539 |
ASSURE [11] IM101031 Phase III | Randomized, placebo-controlled, double-blind/Abatacept Study of Safety in Use with other RA therapies/2002 to 2003 | 12 | 959 | 482 | 1184 |
| Â | Total double-blind 5 core above | Â | 1955 | 989 | 2689** |
ATTEST [15] IM101043 | Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA/2005 to 2006 | 12 | 156 | 110 | 236* (132 aba, 104 placebo, 136 infliximab) |
ARRIVE [16] IM101064 | Abatacept Researched in Rheumatoid arthritis patients with an Inadequate anti-TNF response to Validate Effectiveness/2005 to 2006 | 6 (open-label) | 1046 | Â | 530 |